David W. Goodman, MD: ADHD Presentations at NEI

Video

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

There are a number of new treatments and therapies coming on board for attention deficit/hyperactivity disorder (ADHD).

During the annual Neuroscience Education Institute Max! Virtual meeting, David Goodman, MD, FAPA, assistant professor of psychiatry and behavioral sciences at Johns Hopkins School of Medicine, will present 5 different times about ADHD and some new insights into the disorder.

Goodman explained some of the confusion in ADHD he will address during 1 of his presentations will be the hierarchy of ADHD treatments. Currently, there are at least 29 different ADHD treatments coming from multiple medication families, leading to some confusion among doctors over what the right treatment ultimately is.

Goodman will also look at what the options are for doctors should a patient not respond to the first option for ADHD treatment.

He will also take a deeper dive into dosing during the virtual conference, trying to come up with a best practices checklist clinicians can use to find the right dosing for a given patient.

In the final presentation, Goodman will look at the connection between autism and ADHD and what the common comorbidities could be.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.